MTOR and urogenital neoplasm: Additionally, by accumulating evidence of rejection, such as studies to verify the regimen of immunosuppressive drugs to suppress rejection in renal transplant recipients using ICIs and a comparative study to verify the graft-protective effect of mTOR inhibitors, it would be possible to establish a system for managing kidney transplant rejections during ICI therapy.